Table 3 Demographics and clinical characteristics.
Variable | All N = 49 | Withdrawn N = 22 | Completers N = 27 | P value |
|---|---|---|---|---|
Age (years) | 60 ± 9.3 | 57 ± 7.9 | 62 ± 10.0 | 0.10 |
BMI (kg/m2) | 29.6 ± 5.8 | 28.9 ± 7.1 | 30.2 ± 4.5 | 0.47 |
Race | ||||
 White | 44 (90%) | 20 (90.1%) | 24 (89%) | 0.91 |
Ethnicity | Â | Â | Â | Â |
 Not Hispanic/Latino | 44 (90%) | 20 (90.1%) | 24 (89%) | 0.82 |
Working status (n = 47) | ||||
 Full-time | 21 (45%) | 8 (40%) | 13 (48%) | 0.81 |
 Part-time | 10 (21%) | 5 (25%) | 5 (19%) |  |
 Homemaker | 16 (34%) | 7 (35%) | 9 (33%) |  |
Type of work | ||||
 Professional | 15 (31%) | 6 (27%) | 9 (33%) | 0.55 |
 Manager/Sales/Operative | 11 (22%) | 7 (32%) | 4 (15%) |  |
 Unemployed | 6 (12%) | 2 (9%) | 4 (15%) |  |
 Other | 17 (35%) | 7 (32%) | 10 (37%) |  |
Household income (n = 46) | ||||
 < 50 K | 16 (35%) | 6 (30%) | 10 (39%) | 0.91 |
 50–100 K | 12 (26%) | 5 (25%) | 7 (27%) |  |
 100–150 K | 10 (22%) | 5 (25%) | 5 (19%) |  |
 150 K+ | 8 (17%) | 4 (25%) | 4 (15%) |  |
Education (n = 47) | ||||
 High school—associate’s | 19 (40%) | 8 (40%) | 11 (42%) | 0.82 |
 Bachelor’s | 14 (30%) | 7 (35%) | 7 (26%) |  |
 Graduate + (Master’s/MD/PhD) | 14 (30%) | 5 (25%) | 9 (32%) |  |
Marital status | ||||
 Married/partner | 36 (75%) | 18 (86%) | 18 (67%) | 0.17 |
 Single/divorced/widowed | 12 (25%) | 3 (14%) | 9 (33%) |  |
Cancer stage | ||||
 Stage 0 | 7 (14%) | 5 (22%) | 2 (7%) | 0.35 |
 Stage I | 32 (65%) | 14 (64%) | 18 (67%) |  |
 Stage II | 9 (19%) | 3 (14%) | 6 (22%) |  |
 Stage III | 1 (2%) | 0 | 1 (4%) |  |
Cancer treatment | ||||
 ET | 14 (29%) | 9 (41%) | 5 (18%) | 0.13 |
 RT + ET | 28 (57%) | 12 (54%) | 16 (60%) |  |
 CT ± RT + ET | 4 (8%) | 0 | 4 (15%) |  |
 Refused ET | 3 (6%) | 1 (5%) | 3 (6%) |  |
Menopausal status | ||||
 Pre-Menopausal | 11 (23%) | 6 (27%) | 5 (18%) | 0.73 |
 Post-Menopausal | 35 (71%) | 15 (68%) | 20 (74%) |  |
 Peri-Menopausal | 3 (6%) | 1 (5%) | 2 (8%) |  |
Type of endocrine therapy | ||||
 Anastrozole | 29 (6%) | 11 (52%) | 18 (72%) | 0.21 |
 Letrozole | 6 (13%) | 2 (10%) | 4 (16%) |  |
 Tamoxifen | 11 (24%) | 8 (38%) | 3 (12%) |  |
